Skip to main content
SpringerLink
Log in

The Role of 5α-Reductase Inhibitors (5-ARIs) in Expectant Management of Low-Risk Prostate Cancer

  • Chapter
  • First Online:
Active Surveillance for Localized Prostate Cancer

Part of the book series: Current Clinical Urology ((CCU))

Abstract

Prostate cancer, due to its high prevalence and long latency period, is an ideal candidate for prevention. Considerable effort has been placed on prevention strategies utilizing 5α(alpha)-reductase inhibitors (5-ARIs). In this chapter, we will review the rational and key studies examining the role of these drugs in secondary prevention of prostate cancer among patients with low-risk prostate cancer undergoing active surveillance.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Crook JM, Gomez-Iturriaga A, Wallace K, Ma C, Fung S, Alibhai S, Jewett M, Fleshner N. Comparison of health-related quality of life 5 years after SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial. J Clin Oncol. 2011;29(4):362–8.

    Article  PubMed  Google Scholar 

  2. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358(12): 1250–61.

    Article  PubMed  CAS  Google Scholar 

  3. Garos S, Kluck A, Aronoff D. Prostate cancer patients and their partners: differences in satisfaction indices and psychological variables. J Sex Med. 2007;4(5): 1394–403.

    Article  PubMed  Google Scholar 

  4. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med. 2003;349:366–81.

    Article  PubMed  CAS  Google Scholar 

  5. Thomas LN, Lazier CB, Gupta R, et al. Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate. 2005;63:231–9.

    Article  PubMed  CAS  Google Scholar 

  6. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab. 2004;89: 2179–84.

    Article  PubMed  CAS  Google Scholar 

  7. Thompson IM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215–49.

    Article  PubMed  CAS  Google Scholar 

  8. Andriole GL, et al. effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362:1192–202.

    Article  PubMed  CAS  Google Scholar 

  9. Finelli A, et al. Impact of 5a-reductase inhibitors on Men followed by active surveillance for prostate cancer. Eur Urol. 2011;59(4):509–14.

    Article  PubMed  CAS  Google Scholar 

  10. Fleshner N, Gomella LG, Cookson MS, Finelli A, Evans A, Taneja SS, Lucia MS, Wolford E, Somerville MC, Rittmaster R, REDEEM Study Group. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemp Clin Trials. 2007; 28(6):763–9.

    Article  PubMed  CAS  Google Scholar 

  11. Fleshner NE. REDEEM trial investigators. Dutasteride and active surveillance of low-risk prostate cancer. Lancet. 2012;379(9826):1590.

    Google Scholar 

  12. Fleshner N, Lucia MS, Melich K, Nandy I, Libby Black, Rittmaster R. Effect of dutasteride on prostate cancer progression and cancer diagnosis on rebiopsy in the REDEEM active surveillance study. ASCO 2011.

    Google Scholar 

  13. Fleshner N, Lucia MS, Karen Melich, Indrani Nandy, Libby Black, Rittmaster R. Inhibition of PCa progression by dutasteride and the impact on anxiety, quality of life (QOL), and urinary symptoms in men undergoing active surveillance: REDEEM study results. AUA 2011.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, Division of Urology, Princess Margaret Hospital, University Health Network, Toronto, ON, Canada

    David Margel M.D. & Neil Fleshner M.D., F.R.C.S.C., M.P.H.

Authors
  1. David Margel M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Neil Fleshner M.D., F.R.C.S.C., M.P.H.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Neil Fleshner M.D., F.R.C.S.C., M.P.H. .

Editor information

Editors and Affiliations

  1. University of Toronto, Sunnybrook Health Sciences Centre, Division of Urology, Toronto, M4N 3M5, Ontario, Canada

    Laurence Klotz

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media New York

About this chapter

Cite this chapter

Margel, D., Fleshner, N. (2012). The Role of 5α-Reductase Inhibitors (5-ARIs) in Expectant Management of Low-Risk Prostate Cancer. In: Klotz, L. (eds) Active Surveillance for Localized Prostate Cancer. Current Clinical Urology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-912-9_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-61779-912-9_13

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61779-911-2

  • Online ISBN: 978-1-61779-912-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation